Sugi Predict

Sugi Predict / Compounds / SCHEMBL1979896

SCHEMBL1979896

SCHEMBL1979896

Cc1cccc(C)c1Oc1ccc(NC(=O)C(C)(C)N)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.43
▸ MAPK1 P28482 3/20 0.43
▸ NPSR1 Q6W5P4 2/20 0.43
▸ HTR2C P28335 1/20 0.42
▸ RAB9A P51151 5/20 0.42
▸ PKM P14618 1/20 0.42
▸ GALR3 O60755 1/20 0.42
▸ AR P10275 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ NOTUM Q6P988 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ PABPC1 P11940 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ GAA P10253 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ GFER P55789 1/20 0.39
▸ KEAP1 Q14145 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1980327 0.83 HTR2C (0.42) MAPTMAPK1NPSR1HTR2CRAB9A
SCHEMBL13721575 0.82 PKM (0.40) MAPTMAPK1NPSR1HTR2CRAB9A
SCHEMBL12593958 0.82 HTR2C (0.41) MAPTMAPK1NPSR1HTR2CRAB9A
SCHEMBL13832518 0.81 NOTUM (0.49) MAPTNPSR1HTR2CRAB9APKM
SCHEMBL1979897 0.80 KEAP1 (0.39) MAPTMAPK1NPSR1HTR2CRAB9A
SCHEMBL1979058 0.80 KMT2A (0.46) HTR2CRAB9ANOTUMMEN1PABPC1
SCHEMBL1982716 0.78 MEN1 (0.44) MAPTMAPK1NPSR1HTR2CRAB9A
SCHEMBL12594157 0.75 JAK2 (0.42) MAPK1HTR2CRAB9APKMGALR3
SCHEMBL21980939 0.75 KMT2A (0.42) MAPTMAPK1NPSR1HTR2CRAB9A
SCHEMBL13721302 0.75 KMT2A (0.42) MAPTMAPK1NPSR1HTR2CRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2020-05-28 — — US disclosed
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2020-05-28 — — US disclosed
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 — — US disclosed
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 — — US disclosed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 — — US disclosed
US-10058551-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2018-08-28 — — US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 — — US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 — — US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 — — US disclosed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 — — US disclosed
US-9216967-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2015-12-22 — — US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 — — US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 — — US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 — — EP disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 — — WO disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 MAPT 3762/4885MAPK1 808/4885NPSR1 561/4885
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 MAPT 3762/4885MAPK1 808/4885NPSR1 561/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 MAPT 3762/4885MAPK1 808/4885NPSR1 561/4885
US-10058551-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 MAPT 3762/4885MAPK1 808/4885NPSR1 561/4885
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 MAPT 3762/4885MAPK1 808/4885NPSR1 561/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 MAPT 3789/4885MAPK1 1000/4885NPSR1 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.